COMMUNIQUÉS West-GlobeNewswire

CellaVision AB presents the year-end bulletin for 2017 on February 9 at 11:00 CET
29/01/2018
The information was submitted to the public on January 29, 2018 at 8:20 CET CellaVision will publish the year-end bulletin for 2017 on February 9, 2018 at 08:20 CET. The report will be available at www.cellavision.com [...]
SANOFI TO ACQUIRE ABLYNX FOR €3.9 BILLION
29/01/2018
Regulated information - inside information Strengthens Sanofi's R&D strategy with innovative Nanobody ® technology platform Expands growing rare blood disorders franchise with Ablynx's late-stage investigational [...]
Sanofi to acquire Ablynx for €3.9 Billion
29/01/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi to acquire Ablynx for €3.9 Billion Strengthens Sanofi's R&D strategy with innovative Nanobody ® technology platform Expands growing rare blood [...]
Sanofi va acquérir Ablynx pour 3,9 milliards d'euros
29/01/2018
Communiqué de Presse Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi va acquérir Ablynx pour 3,9 milliards d'euros Renforcement de la stratégie R&D de Sanofi avec une plateforme technologique innovante spécialisée [...]
Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update
29/01/2018
Liestal, Switzerland, January 29, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces preliminary, unaudited key financial figures for 2017. The Company reports an increase of 21% year-on-year in net revenues to CHF [...]
MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France
29/01/2018
LA JOLLA, Calif., Jan. 28, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
VBI Vaccines Announces Changes to its Board of Directors
26/01/2018
Sam Chawla, of Perceptive Advisors, to resign from VBI Board of Directors Tomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI’s Board of Directors CAMBRIDGE, Mass., Jan. 26, 2018 (GLOBE [...]
TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007
26/01/2018
REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 26, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix [...]
Repros Announces Negative Opinion From the EMA for Enclomiphene
26/01/2018
THE WOODLANDS, Texas, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® , (Nasdaq: RPRX ) ("Repros" or the "Company") today announced that, consistent with the previously disclosed guidance from the European [...]
IntelGenx Mourns the Passing of long term Director Ian Troup
26/01/2018
SAINT-LAURENT, Quebec, Jan. 26, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (“IntelGenx”), (TSXV:IGX) (OTCQX:IGXT) -- The Board of Directors of IntelGenx was advised today of the passing of its long term [...]
Aviragen Comments on ISS Report
26/01/2018
Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote FOR the Proposed [...]
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26/01/2018
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera expands Novartis' neuroendocrine tumor [...]
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26/01/2018
First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients LUTATHERA ® marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) [...]
Insmed Announces Closing of Public Offering
26/01/2018
BRIDGEWATER, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ) announced the closing today of its previously announced public offering of its 1.75% convertible senior notes due 2025. Insmed [...]
Skyline Medical Opens New European Headquarters to Drive International Sales of the STREAMWAY System
26/01/2018
MINNEAPOLIS, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Skyline Medical Inc (NASDAQ: SKLN ) (“Skyline” or the “Company”), today announced that it has opened new European headquarters in Belgium and appointed Jean-Paul Rasschaert [...]
American Health Council Honors Gerald Morley, MD as “Best in Medicine”
26/01/2018
NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- The American Health Council honors Gerald Morley, MD as one of America’s “Best in Medicine.” With over 53 years of knowledge and expertise in Clinical Neurophysiology, Dr. [...]
Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock
26/01/2018
NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing of a previously [...]
BioStem Technologies, Inc. Announces the Engagement of Investment Banking Firm Young America Capital for 15 Million Dollar 506(c) Offering.
26/01/2018
Pompano Beach, FL, Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BSEM” or “Company”) announced today the engagement of investment banking firm Young America Capital as an advisor for [...]
Aquinox to Host Analyst and Investor Event in New York City
26/01/2018
VANCOUVER, British Columbia, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ: AQXP ), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to [...]

Pages